Inhibition of proliferation of PC‐3 human prostate cancer by antagonists of growth hormone–releasing hormone: Lack of correlation with the levels of serum IGF‐I and expression of tumoral IGF‐II and vascular endothelial growth factor
- 17 June 2002
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 52 (3) , 173-182
Abstract
BACKGROUND: Antagonists of growth hormone–releasing hormone (GHRH) such as JV‐1‐38 can inhibit androgen‐independent prostate cancer directly by several mechanisms and/or indirectly by suppressing growth hormone/insulin‐like growth factor‐I (GH/IGF‐I) axis. To shed more light on the mechanisms involved, the effects of JV‐1‐38 on PC‐3 human prostate cancer were compared with those of somatostatin analog RC‐160 in vivo and in vitro.METHODS: Nude mice bearing PC‐3 tumors received JV‐1‐38 (20 μg), RC‐160 (50 μg) or a combination of JV‐1‐38 and RC‐160. The concentration of IGF‐I in serum and the expression of mRNA for IGF‐II and vascular endothelial growth factor (VEGF) in tumor tissue were investigated.RESULTS: In vivo, the final volume of PC‐3 tumors treated with JV‐1‐38 was significantly lowered by 49% (P < 0.01), whereas RC‐160 exerted only 30% inhibition (NS), compared with controls. Combined use of both compounds augmented tumor inhibition to 63% (P < 0.001). Serum IGF‐I levels were decreased only in mice treated with RC‐160. JV‐1‐38 suppressed mRNA for IGF‐II in PC‐3 tumors by 42%, whereas RC‐160 alone or in combination with JV‐1‐38 caused a 65% reduction. JV‐1‐38 and RC‐160 used as single drugs decreased the expression of VEGF by 50%, and their combination caused a 63% reduction. In vitro, JV‐1‐38 inhibited the proliferation of PC‐3 cells by 39%. This effect could be partially reversed by addition of IGF‐I to the serum‐free medium. RC‐160 alone did not affect the PC‐3 cell growth in vitro, but in combination with JV‐1‐38 it augmented the antiproliferative effect of the GH‐RH antagonist to 72%. Exposure to JV‐1‐38 in vitro reduced the expression of mRNA for IGF‐II in PC‐3 cells by 55% but did not change VEGF mRNA levels, whereas RC‐160 had no effect.CONCLUSIONS: The antiproliferative effect of JV‐1‐38 was not associated with the suppression of serum IGF‐I and was only partially correlated with the expression of IGF‐II and VEGF in PC‐3 tumors, suggesting that other mechanisms play a role in the antitumor action of GHRH antagonists. Nevertheless, the stronger inhibition of tumor growth after combined treatment with JV‐1‐38 and RC‐160 indicates that the interference with multiple local stimulatory factors leads to an enhanced inhibition of prostate cancer. Prostate 52:173–182, 2002.Keywords
This publication has 33 references indexed in Scilit:
- Antagonistic Analogs of Growth Hormone-releasing Hormone: New Potential Antitumor AgentsTrends in Endocrinology & Metabolism, 1999
- Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitroProceedings of the National Academy of Sciences, 1999
- Peptide Growth Factors and Prostate Cancer: New Models, New OpportunitiesCancer and Metastasis Reviews, 1998
- MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTSJournal of Urology, 1998
- Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumorsProceedings of the National Academy of Sciences, 1998
- Insulin-Like Growth Factor 1 and Prostate Cancer Risk: A Population-Based, Case-Control StudyJNCI: Journal of the National Cancer Institute, 1998
- Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cellsBritish Journal of Cancer, 1998
- Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective StudyScience, 1998
- Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormoneBritish Journal of Cancer, 1997
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989